TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Genprex ( (GNPX) ) is now available.
On November 4, 2025, Genprex announced that the European Patent Office intends to grant a patent for Reqorsa® Gene Therapy in combination with PD-1 antibodies for cancer treatment. This potential patent expands on existing patents in several countries and highlights Reqorsa’s potential to enhance current cancer therapies, particularly for lung cancer.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. Its primary product, Reqorsa® Gene Therapy, is being developed to treat lung cancer in combination with approved cancer drugs.
Average Trading Volume: 714,848
Technical Sentiment Signal: Sell
Current Market Cap: $8.65M
See more insights into GNPX stock on TipRanks’ Stock Analysis page.